Type 2 & other diabetes

Dose–Response Association Between Systemic and Dermatologic Glucocorticoid Use and Type 2 Diabetes Mellitus: A Nationwide Case–Control Study

Diabetes Obes MetabPublished Nationwide case–control study

Authors' conclusion

Systemic and dermatologic glucocorticoid use was associated with a clear dose-dependent increase in Type 2 diabetes mellitus odds, including at doses < 2.5 mg/day. Other topical routes appeared metabolically safe.

Study context

Population
People aged ≥40 years with incident T2D and matched controls, Danish registry data 2013–2021matched 1:3
Participants
149,113 vs 447,339
Exposure
Systemic and topical glucocorticoid use vs no use, by daily prednisolone-equivalent dose
  • Casesn = 149,113
  • Controlsn = 447,339reference
Outcome
Odds of T2D by glucocorticoid exposure (≥1 prescription within 1 year before diagnosis and ≥2 within 3 years) and daily prednisolone-equivalent dose
Methodological detailsregistry-based, matched 1:3 by age, sex and weighted Charlson Comorbidity Index, conditional logistic regression
  • Registry-based
  • Matched 1:3 by age, sex and weighted Charlson Comorbidity Index
  • Conditional logistic regression

Main finding

As reported in the abstract

Odds of T2D by oral systemic glucocorticoid dose
Adjusted odds ratio (95% CI)
Oral systemic <2.5 mg/day
1.25(1.21–1.29)
Oral systemic 2.5-7.4 mg/day
1.49(1.43–1.56)
Oral systemic ≥7.5 mg/day
3.02(2.90–3.15)

Observational data: associations, not effects.

Further findings

Odds of T2D by dermatologic glucocorticoid dose

OR (95% CI)
Dermatologic <2.5 mg/day1.21 (1.18–1.23)
Dermatologic ≥7.5 mg/day1.51 (1.40–1.63)

Nasal, rectal, ophthalmic or otic glucocorticoids

No progressively significant associations after adjustment

Original publication

Dose–Response Association Between Systemic and Dermatologic Glucocorticoid Use and Type 2 Diabetes Mellitus: A Nationwide Case–Control Study. Diabetes Obes Metab. Published 16 June 2026. doi:10.1111/dom.71001

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.